Neutrophil-dependent tumor rejection and priming of tumoricidal CD8 + T cell response induced by dendritic cells overexpressing CD95L

Journal of Leukocyte Biology

Volumn 84, Issue 3, 2008, Pages 713-720

  Buonocore, Sofia ^a   Haddou, Najate Ouled ^a   Moore, Fabrice ^a   Florquin, Sandrine ^b   Paulart, Frédéric ^a   Heirman, Carlo ^c   Thielemans, Kris ^c   Goldman, Michel ^a   Flamand, Véronique ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

CD95 ligand; Immunotherapy; Murine model

Indexed keywords

FAS LIGAND; GAMMA INTERFERON;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CYTOKINE PRODUCTION; DENDRITIC CELL; HISTOPATHOLOGY; INNATE IMMUNITY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR REGRESSION; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; BONE MARROW; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; DENDRITIC CELLS; FAS LIGAND PROTEIN; GENES, MHC CLASS I; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; NEUTROPHILS; OVALBUMIN; PEPTIDE FRAGMENTS; RETROVIRIDAE; SKIN TRANSPLANTATION; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; THYMOMA; TRANSFECTION; VACCINATION;

ANIMALIA; MURINAE;

EID: 50849142911     PISSN: 07415400     EISSN: None     Source Type: Journal    
DOI: 10.1189/jlb.0108075     Document Type: Article

References (38)

1. Nagata, S., Suda, T. (1995) Fas and Fas ligand: lpr and gld mutations. Immunol. Today 16, 39-43.
2. Ferguson, T. A., Griffith, T. S. (2006) A vision of cell death: Fas ligand and immune privilege 10 years later. Immunol. Rev. 213, 228-238.
3. Hahne, M., Rimoldi, D., Schröter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., Tschopp, J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366.
4. Askenasy, N., Yolcu, E. S., Yaniv, I., Shirwan, H. (2005) Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 105, 1396-1404.
5. Tourneur, L., Malassagne, B., Batteux, F., Fabre, M., Mistou, S., Lallemand, E., Lores, P., Chiocchia, G. (2001) Transgenic expression of CD95 ligand on thyroid follicular cells confers immune privilege upon thyroid allografts. J. Immunol. 167, 1338-1346.
6. Allison, J., Georgiou, H. M., Strasser, A., Vaux, D. L. (1997) Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc. Natl. Acad. Sci. USA 94, 3943-3947.
7. Kang, S. M., Schneider, D. B., Lin, Z., Hanahan, D., Dichek, D. A., Stock, P. G., Baekkeskov, S. (1997) Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3, 738-743.
8. Coussens, L. M., Werb, Z. (2001) Inflammatory cells and cancer: think different! J. Exp. Med. 193, F23-F26.
9. Schmielau, J., Finn, O. J. (2001) Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res. 61, 4756-4760.
10. Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., Musiani, P. (2001) The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339-345.
11. Otten, M. A., Rudolph, E., Dechant, M., Tuk, C. W., Reijmers, R. M., Beelen, R. H., van de Winkel, J. G., van Egmond, M. (2005) Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J. Immunol. 174, 5472-5480.
12. O'Connell, J., Houston, A., Bennett, M. W., O'Sullivan, G. C., Shanahan, F. (2001) Immune privilege or inflammation? Insights into the Fas ligand enigma. Nat. Med. 7, 271-274.
13. Hohlbaum, A. M., Gregory, M. S., Ju, S. T., Marshak-Rothstein, A. (2001) Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J. Immunol. 167, 6217-6224.
14. Rescigno, M., Piguet, V., Valzasina, B., Lens, S., Zubler, R., French, L., Kindler, V., Tschopp, J., Ricciardi-Castagnoli, P. (2000) Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1β, and the production of interferon γ in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J. Exp. Med. 192, 1661-1668.
15. Kidoya, H., Umemura, M., Kawabe, T., Matsuzaki, G., Yahagi, A., Imamura, R., Suda, T. (2005) Fas ligand induces cell-autonomous IL-23 production in dendritic cells, a mechanism for Fas ligand-induced IL-17 production. J. Immunol. 175, 8024-8031.
16. Buonocore, S., Paulart, F., Le Moine, A., Braun, M., Salmon, I., Van Meirvenne, S., Thielemans, K., Goldman, M., Flamand, V. (2003) Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood 101, 1469-1476.
17. Cairns, C. M., Gordon, J. R., Li, F., Baca-Estrada, M. E., Moyana, T., Xiang, J. (2001) Lymphotactin expression by engineered myeloma cells drives tumor regression: mediation by CD4+ and CD8+ T cells and neutrophils expressing XCR1 receptor. J. Immunol. 167, 57-65.
18. Graf, M. R., Prins, R. M., Merchant, R. E. (2001) IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J. Immunol. 166, 121-129.
19. Seino, K., Kayagaki, N., Okumura, K., Yagita, H. (1997) Antitumor effect of locally produced CD95 ligand. Nat. Med. 3, 165-170.
20. De Veerman, M., Heirman, C., Van Meirvenne, S., Devos, S., Corthals, J., Moser, M., Thielemans, K. (1999) Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J. Immunol. 162, 144-151.
21. Olivares Fontt, E., Heirman, C., Thielemans, K., Vray, B. (1996) Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Infect. Immun. 64, 3429-3434.
22. Ottonello, L., Tortolina, G., Amelotti, M., Dallegri, F. (1999) Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J. Immunol. 162, 3601-3606.
23. Chen, J. J., Sun, Y., Nabel, G. J. (1998) Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717.
24. Albert, M. L., Sauter, B., Bhardwaj, N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89.
25. Ochsenbein, A. F., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., Hengartner, H., Zinkernagel, R. M. (2001) Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411, 1058-1064.
26. Van der Bruggen, P., Van den Eynde, B. J. (2006) Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18, 98-104.
27. Scheinecker, C., McHugh, R., Shevach, E. M., Germain, R. N. (2002) Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J. Exp. Med. 196, 1079-1090.
28. Liu, K., Iyoda, T., Saternus, M., Kimura, Y., Inaba, K., Steinman, R. M. (2002) Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. 196, 1091-1097.
29. Zimmermann, V. S., Bondanza, A., Monno, A., Rovere-Querini, P., Corti, A., Manfredi, A. A. (2004) TNF-α coupled to membrane of apoptotic cells favors the cross-priming to melanoma antigens. J. Immunol. 172, 2643-2650.
30. Tada, Y., O-Wang, J., Takiguchi, Y., Tatsumi, K., Kuriyama, T., Okada, S., Tokuhisa, T., Sakiyama, S., Tagawa, M. (2002) Cutting edge: a novel role for Fas ligand in facilitating antigen acquisition by dendritic cells. J. Immunol. 169, 2241-2245.
31. L and resistance to CD95-mediated apoptosis of monocyte-derived dendritic cells: inhibition by bisindolylmaleimide. Blood 95, 3478-3482.
32. Correale, P., Cusi, M. G., Del Vecchio, M. T., Aquino, A., Prete, S. P., Tsang, K. Y., Micheli, L., Nencini, C., La Placa, M., Montagnani, F., Terrosi, C., Caraglia, M., Formica, V., Giorgi, G., Bonmassar, E., Francini, G. (2005) Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J. Immunol. 175, 820-828.
33. + T-cell immunity. J. Immunother. 29, 545-557.
34. van Gisbergen, K. P., Geijtenbeek, T. B., van Kooyk, Y. (2005) Close encounters of neutrophils and DCs. Trends Immunol. 26, 626-631.
35. Wittamer, V., Bondue, B., Guillabert, A., Vassart, G., Parmentier, M., Communi, D. (2005) Neutrophil-mediated maturation of chemerin: a link between innate and adaptive immunity. J. Immunol. 175, 487-493.
36. Yang, D., Chen, Q., Chertov, O., Oppenheim, J. J. (2000) Human neutrophil defensins selectively chemoattract naive T and immature dendritic cells. J. Leukoc. Biol. 68, 9-14.
37. Van Gisbergen, K. P., Sanchez-Hernandez, M., Geijtenbeek, T. B., van Kooyk, Y. (2005) Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. J. Exp. Med. 201, 1281-1292.
38. Bennouna, S., Bliss, S. K., Curiel, T. J., Denkers, E. Y. (2003) Cross-talk in the innate immune system: neutrophils instruct recruitment and activation of dendritic cells during microbial infection. J. Immunol. 171, 6052-6058.